

Overview of Anacor Pharmaceuticals



Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.

Anacor's mission is to improve healthcare through unconventional thinking.

Anacor's objective is to discover, develop and commercialize proprietary boron-based drug compounds with superior efficacy, safety and convenience for the treatment of a variety of diseases.

Anacor's first approved drug, KERYDIN® (tavaborole) topical solution, 5%, is an oxaborole antifungal approved by the U.S. Food and Drug Administration in July 2014 for the topical treatment of onychomycosis of the toenails.

- Anacor entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which PharmaDerm, the branded dermatology division of Sandoz, distributes and commercializes KERYDIN in the United States.

Crisaborole Topical Ointment, 2%, is Anacor's lead topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis, chronic inflammatory diseases that affect millions of people worldwide.

- If approved, crisaborole would be the first topical non-steroidal treatment that inhibits TNF-alpha release.
- Anacor completed enrollment in two pivotal Phase 3 clinical trials of Crisaborole Topical Ointment, 2%, in patients with mild-to-moderate atopic dermatitis. The company to expects to announce data from the two trials in 3Q 2015.

Ticker Symbol	ANAC
Market Cap	3.44 billion
IPO	November 24, 2010
# of Products in Development	4
# of Employees	100
Founded	2002
Headquarters	Palo Alto, Calif.

Developing Small-Molecule Therapeutics Derived From Our Boron Chemistry Platform